Brief: Hyloris Partners With Vaneltix For Interstitial Cystitis Pain Treatment

Hyloris Pharmaceuticals SA

17/12/2021 06:11

Dec 17 (Reuters) - Hyloris Pharmaceuticals SA  HYL.BR :
    * ENTERS INTO STRATEGIC PARTNERSHIP WITH VANELTIX FOR
TREATMENT OF
ACUTE PAIN IN INTERSTITIAL CYSTITIS
    * ADDRESSABLE PATIENT POPULATION OF AT LEAST 6 MILLION IN
U.S.
    * ALENURA WILL BE SUPPLIED AS A PREFILLED SYRINGE FOR
INTRA-VESICULAR ADMINISTRATION TO BLADDER THROUGH AN
INSTALLATION PROCEDURE AND IS PROTECTED BY MULTIPLE PATENTS AND
PATENT APPLICATIONS POTENTIALLY PROVIDING EXCLUSIVITY UP TO 2038
    * WE ARE NOW PREPARING NEXT STEPS AND ANTICIPATE START OF A
LARGER
PHASE 2 COMPARATIVE STUDY AND A PHASE 2 MULTIDOSE STUDY MID 2022
FOR WHICH RESULTS COULD BE AVAILABLE BYLATE 2023 - CEO
    * WILL PROVIDE STAGED INVESTMENTS OF IN TOTAL MAXIMUM USD
6.7 MIO
FOR PHASE 2, MANUFACTURING AND REGULATORY RELATED ACTIVITIES AND
A LOAN OF USD 0.5 MIO
    * WILL BE ELIGIBLE TO RECEIVE A TIERED PERCENTAGE OF PRODUCT
MARGIN GENERATED BY VANELTIX

Source text for Eikon:  ID:nGNE20g0Ql 
Further company coverage:  HYL.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))